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ABSTRACT
The etiology of acute myeloid leukemia (AML) is largely unknown.  Biological and 
epidemiological  data  implicate  exogenous  toxicants  including  cytotoxic  drugs, 
benzene,  radiation  and  cigarette  smoking.    Allelic  variation  in  genes  encoding 
enzymes such as NADP(H) quinone oxidoreductase and glutathione S-transferase 
T1 that metabolise environmental toxicants predispose to sub-types of AML including 
therapy-related  AML.  We  assayed  NRAS  oncogene  mutation  and  FLT3  internal 
tandem  duplication in  447  AML  patients  selected  for  an abnormal  karyotype  from 
those  treated  within  the  MRC  AML  10,  11  and  12  clinical  trials.  Functional  allelic 
variant  frequencies  in  genes  encoding  carcinogen-metabolising  enzymes  GSTT1, 
GSTM1,  CYP1A1,  CYP2D6,  CYP2C19,  SULT1A1  and  NQO1  were  previously 
determined for this cohort.  FLT3 ITD frequency was 17% and NRAS mutation 12% 
for the entire selected cohort. Both mutations were found together in only 4 patients. 
No  association  was  found  between  enzyme  allelic  variant  frequencies  and  the 
presence  of  FLT3  ITD  for  the  entire  cohort  or  within  cytogenetic  subgroups. 
CYP1A1*2B (Val) high-inducibility variant allele was over-represented in patients with 
NRAS mutation compared with no mutation, for a) the entire AML cohort (n=8/53 vs. 
26/371; OR=2.36, 95%CI 1.01-5.53), and b) the poor-risk karyotype group comprising 
patients  with  partial/complete  deletion  of  chromosome  5  or  7,  or  abnormalities  of 
chromosome 3 (n=6/14 vs. 4/89; OR=15.94, 95%CI 3.71-68.52). The CYP1A1*2B 
allele may predispose to the development of these sub-groups of AML by augmented 
phase 1 metabolism to highly reactive intermediates of CYP1A1 substrates including 
polycyclic aromatic hydrocarbons, or by generation of oxidative stress as a metabolic 
by-product.
Email d.t.bowen@dundee.ac.uk
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Introduction
The etiology of acute myeloid leukemia (AML) is unknown for the majority of cases.  
The identification of biologically well-defined subgroups based upon cytogenetic 
analysis has improved prognostic power and led to risk-directed therapeutic 
strategies.  It is increasingly clear that the etiological mechanisms underlying the 
"good-risk" translocational karyotypes t(15:17), inv(16) and t(8:21) which predominate 
in younger patients will differ from the largely deletional abnormalities seen in "poor 
risk" disease which in turn are more common in older patients.  The karyotypic 
similarities between therapy-related AML (t - AML) and poor-risk de novo AML
1
suggest that an environmental etiology is more likely in the latter group than in the  de 
novo "good risk" group.  Questionnaire-based case-control studies have suggested 
associations between exposure to specific environmental toxicants and the 
development of AML, but cannot define mechanisms of leukemogenesis.
2,3
The cytochrome P450 enzymes are expressed predominantly in the liver and function 
to detoxify many environmental toxicants (xenobiotics).  These Phase 1 metabolic 
enzymes transfer electrons onto substrate toxicants to create highly reactive 
intermediates which are then available for detoxification by a variety of phase 2 
enzymes including glutathione S-transferases and sulfotransferases.
Several carcinogen-metabolising genes with functional allelic variants are now known 
to predispose to t-AML
4,5 and also to de novo AML.
6-8  Furthermore this 
predisposition may be greater or less in sub-groups of AML defined by specific 
genomic damage at the karyotypic level.  The paradigm for an AML predisposition 
gene encoding a carcinogen-metabolising enzyme is NADP(H) quinone 
oxidoreductase (NQO1).  The C609T polymorphic variant, which confers reduced 
phase 2 metabolism is associated with a predisposition to therapy-related AML
4 and 
selected cytogenetic sub-groups of de novo AML.
6  Reduced phase 2 metabolism 
has the potential to result in an accumulation of reactive intermediates which in turn 
oxidise DNA and protein, leading to DNA mutation and / or cell death.  Phase 1 
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enzymes with functionally-relevant allelic variants are also predisposition genes for 
AML and include CYP2C19 and CYP2D6.
8  The proposed mechanism of 
predisposition for these latter genes is a consequence of reduced phase 1 
metabolism presumably allowing the accumulation of non-metabolised toxic 
carcinogens.
We selected functional polymorphic variants in specific carcinogen metabolising 
enzymes for study.  Enzymes were selected on the basis of an established role in the 
metabolism of known leukemogenic compounds (e.g. benzene, cytotoxic 
chemotherapeutic drugs).  We then selected only patients with well-characterised 
karyotypic abnormalities, to include those known to occur following genotoxic insult 
(e.g. chromosome 5 and 7 abnormalities) and also good-prognosis translocations for 
which an environmental etiology may be less likely.  Finally we assayed the two most 
common molecular abnormalities in AML, namely FLT3 internal tandem duplication 
(ITD) and NRAS mutation; each of which is likely to arise from a different mechanism.
We demonstrate that the *2B high-inducibility variant of cytochrome P4501A1 (CYP 
1A1) is over-represented in a sub-group of poor-risk AML patients with NRAS
mutation and may represent a predisposition allele for these specific forms of 
genomic damage in AML.
Materials and methods
Patients
Four hundred and forty seven patients with de novo or secondary AML (defined as 
secondary to chemotherapy, or following an antecedent hematologic disorder), and 
who were entered into the Medical Research Council (MRC) AML 10 (<60 years, 
n=109), 11 (>55 years, n=115) and 12 (<60 years, n=223) clinical trials were studied.  
This patient cohort overlaps with previously published studies.
6  Median age was 46 
years (range 15-79).  DNA was extracted from presentation bone marrow by 
dodecyltrimethylammonium bromide lysis
9 and stored at University College London.  
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Cytogenetic classification
Most cytogenetic studies were done in local laboratories, all participants in a central 
quality control scheme (UK National External Quality Assessment Scheme).  Where 
this was not available, cytogenetic analyses were done at a central facility in 
University College London.  Standard methods of bone marrow culture were used, 20 
metaphases fully analysed, and reported in accordance with the International System 
for Human Cytogenetic nomenclature (ISCN) guidelines.
10  An hierarchical 
cytogenetic classification was used to assign all patients to a cytogenetic subgroup 
as previously described.
11 For patients with more than one chromosomal abnormality 
the subgroup assigned was determined by the most important abnormality in the 
following order; established translocation > established deletion > established trisomy 
> non-established translocation > non-established deletion > non-established 
trisomy.
11  Data in this study are now presented for cytogenetic "risk" groups based 
on the MRC hierarchical classification
12 and defined here as: a) "good-risk"; t(15;17), 
t(8;21), inv(16), b) poor-risk; partial or complete deletion of chromosomes 5 and 7 
(5q/7q), abnormalities of 3q; and c) "intermediate-risk"; including +8, 11q23 
abnormalities, +11, 17p-, +21, 20q-, 12p- (but excluding normal karyotype).
Carcinogen-metabolising enzyme gene allelic variant analysis
Assays for allelic variants at the following loci have been described previously:
GSTM1 (null), GSTT1 (null),
7 CYP2D6 (poor/extensive metaboliser), CYP 2C19*2 
(681G￿A; aberrant splice), CYP1A1*2B allele (2455A￿G, Ile￿Val),
8 and NQO1 
(609C￿T;Pro￿Ser).
6  In addition a polymorphism in sulfotransferase (SULT) 1A1 
(*2, 213G￿A; Arg￿His) was assayed by allelic discrimination using the polymerase 
chain reaction (PCR) based TaqMan
￿ technology (PE Applied Biosystems). Primer 
and probe sequences for this assay were as follows: 
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Forward primer 5' GGTTGAGGAGTTGGCTCTGC 3' (300nM), reverse primer 
5'ACGTGTGCTGAACCATGAAGT 3'(300nM)(Annealing temperature = 62
oC), WT 
probe 5'AGTTTGTGGGGCGCTCCCTG 3'(100nM)(Tet labelled), variant probe 
5'AGTTTGTGGGGCACTCCCTGC 3'(200nM)(Fam labelled).
FLT3 internal tandem duplication assay
Genomic DNA was amplified from Exons 12 and 13 of the FLT3 gene.
13  This 
produced a wild type fragment of 328 bases plus a higher molecular weight fragment 
containing internal tandem duplicated sequences (when present) of varying length as 
previously described.
13,14  Bands with higher molecular weight than wild type were cut 
from the gel and directly sequenced using a fluorescent primer adapted chain-
termination method
15 on an ABI 3100 sequencer in order to determine the start site 
and size of each duplication.
NRAS mutational analysis
Mutation screen
Separate assays were developed for mutation detection at "hot-spots" in codons 
12/13 (exon 1) and codon 61 (exon 2).  Oligonucleotide primers amplifying short 
fragments (241 base pairs exon 1; 201 base pairs exon 2) were designed for PCR as 
follows: N12/13 assay, Forward 5’ GACTGAGTACAAACTGGTGG 3’, reverse 
5’TGCATAACTGAATGTATACCC 3’; N61 assay, forward 
5’CAAGTGGTTATAGATGGTGAAACC 3’, reverse 
5’AAGATCATCCTTTCAGAGAAAATAAT 3’.  PCR products were then subjected to 
denaturing heteroduplex HPLC analysis (dHPLC, Transgenomics WAVE￿). PCR 
conditions were as follows: a) Exon 1; HotStarTaq￿ (Qiagen) 0.625 units, Primers 
(12.5pmol) N12/13 Forward, N12/13 Reverse, denaturing 95
oC  -  15min: 94
oC- 30sec, 
annealing 55.5
oC- 1 min, extension 72
oC- 1min for 35 cycles: Final cycle 72
oC- 10 
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min.  b) Exon 2; HotStarTaq￿ (Qiagen) 0.625 units, Primers (12.5pmol) N61F 
forward, N61R reverse, denaturing 95
oC  -  15min: 94
oC- 30sec, annealing 55.5
oC- 1 
min, extension 72
oC- 1min for 35 cycles: Final cycle 72
oC- 10 min.  Heteroduplexes 
were then generated using a thermal cycler as follows: 95
oC- 5min; 95
oC- reducing at 
1
oC per 22 sec for 70 cycles. Ten µl heteroduplexed PCR product per well was 
loaded from 96 well plates and analysed by dHPLC using the following conditions: 
Flow 0.9ml/min, 47-52%B in 0.1min, to 60%B in 4min at 61
oC.  Representative 
dHPLC plots are shown in Figure 1.
Figure 1. Denaturing HPLC profiles from representative AML patient DNA 
containing A. wild type codon 12/13 NRAS sequence only and B. wild type plus 
mutant.  In profile B. wild type homoduplexes are retained on the dHPLC column for 
longer (6.36 minutes) than mutant/wild type heteroduplexes (5.97 minutes).
A.
B.
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Mutation confirmation
Samples exhibiting an abnormal dHPLC profile were confirmed as mutant by one or 
both of direct sequencing and/or PCR-restriction fragment length polymorphism 
mutation-sensitive digestion analysis for codons 12
16 and 13.
17  If these assays were 
insufficiently sensitive to confirm mutation, PCR products were cloned (Original TA 
Cloning Kit, Invitrogen, Groningen, Netherlands) and sequenced as above.
15  The 
sensitivity of the dHPLC is such that 15% mutant DNA can be confidently detected in 
a sample containing wild type and mutant sequence (manuscript in preparation).
Statistical analysis
CYP 1A1 allellic variants were analysed as dichotomous variables (Ile/Val +  Val/Val
versus Ile/Ile).  Odds Ratios (ORs) and 95% confidence intervals were calculated 
from 2 x 2 tables for mutant versus non-mutant (NRAS or FLT3) and Ile/Val +  Val/Val
versus Ile/Ile. Logistic regression was used to test these associations within the entire 
cohort and also between the 3 cytogenetic risk groups. Power calculations were 
prospectively computed to inform sample size for the case-control study reported 
elsewhere,
6 and were based upon expected enzyme variant polymorphism 
frequencies. These prospective calculations were not done for NRAS or FLT3 ITD
frequency within the patient cohort alone. Retrospective power calculations were 
performed assuming an expected CYP 1A1 *2B allele variant frequency (Ile/Val + 
Val/Val) of 11%,
8  a FLT3 ITD mutant frequency of 25%,
14 and a NRAS mutant 
frequency of 15%. The sample size of 427 patients was sufficient to provide 80% 
power at P<.05 to detect an Odds Ratio (OR) of 2.5 for the difference in CYP 1A1 
*2B variant frequency between FLT3 ITD mutant versus no ITD, and an OR of 2.9 for 
NRAS mutation versus no mutant. 
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Results
FLT3 ITD frequency was 17% (77/447) and NRAS mutation 12% (53/443) for the 
entire cytogenetically-selected AML cohort.  Both mutations were found together in 
only 4 patients, confirming previous observations.
18
Presence of FLT3 ITD is not associated with variant allele frequency in carcinogen-
metabolising enzymes
No differences in carcinogen-metabolising enzyme variant allele frequency were 
found for GSTT1, GSTM1, CYP2D6, CYP2C19, CYP 1A1, SULT1A1 or NQO1, either 
for the presence versus absence of FLT3 ITD (data for CYP1A1 variant alleles shown 
in Table 1) or in relation to start site / duplication size (data not shown).
Table 1. CYP1A1 allele frequency in AML patients (all cases and sub-groups) 
with or without FLT3 internal tandem duplication. Abbreviations: Ile/Ile = 
homozygous for common Caucasian Ile allele. Ile/Val or Val/Val = heterozygous or 
homozygous for the *2B Val allele respectively.
CYP1A1 allele frequency
FLT3 ITD (%) No ITD (%) Odds Ratio 95% CI
All cases (n=427)
Ile/Ile 67 (93) 326 (92)
Ile/Val or 
Val/Val
5 (7) 29 (8) 0.84 0.31-2.25
"Good risk" karyotypes: t(15;17), t(8;21), inv(16)
Ile/Ile 48 (94) 154 (91)
Ile/Val or 
Val/Val
3 (6) 15 (9) 0.64 0.18-2.31
"Intermediate" karyotypes
Ile/Ile 14 (100) 77 (94)
Ile/Val or 
Val/Val
0 (0) 5 (6) 0.49 0.02-9.3
"Poor-risk" karyotypes: 5q/7q or 3q
Ile/Ile 5 (71) 95 (91)
Ile/Val or 
Val/Val
2 (19) 9 (9) 4.22 0.71-25.0
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CYP 1A1*2B allele is over - represented in AML with NRAS mutation
Patients with NRAS mutant AML had a higher frequency of the CYP 1A1*2B allele 
(combined Ile/Val +  Val/Val ) compared with non-mutant AML cases (z=2.0, P<.045; 
Table 2).  When the cohort was subdivided by cytogenetic risk group, this association 
was confined to the poor-risk karyotype group (Table 2), which was in turn statistically 
significantly different (logisitic regression) from the good-risk group alone (z=2.78, 
P<.005), the intermediate-risk group alone (z=2.0, P <.045) and from the combined 
good plus intermediate risk groups (z=3.026, P<.005). 
The poor-risk group comprised patients with abnormalities of chromosomes 5 and/or 
7 (5q/7q) and also patients with abnormalities of 3q. The frequency of the *2B allele 
in patients with 5q/7q abnormalities was 4/7 for NRAS mutant patients versus 4/79 for 
non-mutant.  Corresponding frequencies for the 3q group were 2/7 for NRAS mutant 
patients versus 0/10 for non-mutant.  
No difference in variant allele frequency was found for GSTT1, GSTM1, CYP2D6, 
CYP2C19, SULT1A1 or NQO1 when NRAS mutant and non-mutant AML groups 
were compared.
The CYP 1A1*2B allele is not associated with a specific NRAS signature mutation
The NRAS mutation spectrum for patients with the CYP 1A1*2B allele is presented in 
Table 3.  Codon 12 mutations were most frequent; 6/7 of those mutations at "hot-
spot" sites, compared with 24/45 mutations at codon 12 amongst patients lacking the 
*2B allele (not significant).  The other base change at codon 33 is a novel NRAS
mutation in a patient with trisomy 8.
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Table 2.  CYP1A1 allele frequency in AML patients (all cases and sub-groups) 
with or without NRAS mutation.  Abbreviations: Ile/Ile = homozygous for common 
Caucasian Ile allele. Ile/Val or Val/Val = heterozygous or homozygous for the *2B Val
allele respectively. 
CYP1A1 allele frequency
NRAS mutant (%) No mutant (%) Odds Ratio 95% CI
All cases (n=424)
Ile/Ile 45 (84.9) 345 (93) - -
Ile/Val or 
Val/Val
8  (15.1) 26 (7) 2.36 1.01-5.53
"Good risk" karyotypes: t(15;17), t(8;21), inv(16)
Ile/Ile 24 (96) 190 (88)
Ile/Val or 
Val/Val
1 (4) 17 (12) 0.46 0.06-3.66
"Intermediate" karyotypes
Ile/Ile 13 (93) 70 (93)
Ile/Val or 
Val/Val
1 (7) 5 (7) 1.08 0.12-9.99
"Poor-risk" karyotypes: 5q/7q or 3q
Ile/Ile 8 (57) 85 (96) - -
Ile/Val or 
Val/Val
6 (43) 4 (4) 15.94 3.71-68.52
Table 3. Mutation spectrum for NRAS mutant AML patients with the CYP1A1*2B 
(Val) allele.
Karyotype CYP1A1 allele Mutation: codon/base substitution/
amino acid change
5q/7q Ile/Val 12.2 G ￿ A / Gly￿Asp
5q/7q Ile/Val 12.2 G ￿ A / Gly￿Asp
5q/7q Ile/Val 61.1 C ￿ A / Gln￿Lys
5q/7q Val/Val 12.2 G ￿ A / Gly￿Asp
3q Ile/Val 12.1 G ￿ A / Gly￿Ser
3q Val/Val 12.2 G ￿ C / Gly￿Ala
+8 Ile/Val 33.3 T ￿ G / Asp￿Glu
t(15;17) Ile/Val 12.1 G ￿ A / Gly￿Ser
Discussion
We have previously observed that the allele frequency for the CYP1A1*2B variant is 
no different in AML patients from controls
8 and cannot therefore be considered a 
predisposition allele for the development of all types of AML.  We now show that the 
CYP1A1*2B allele may indeed predispose patients to develop a sub-group of AML 
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characterised by specific genomic damage namely NRAS mutation and poor-risk 
karyotype.  
CYP1A1 is a phase 1 detoxification enzyme, expressed predominantly in extra-
hepatic tissue and with a wide variety of substrates, including the carcinogenic 
polycyclic aromatic hydrocarbons (PAH).  Baseline cellular expression of CYP1A1 is 
usually low, but high inducibility is mediated through the binding of inducers such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and PAH to a cellular protein, the aryl 
hydrocarbon receptor (AhR).  AhR is in turn bound to Hsp90 and re leases this before 
translocation to the nucleus to associate with another protein the Ah receptor nuclear 
translocator (Arnt).  This complex binds an enhancer sequence activating 
transcriptional induction of CYP1A1 mRNA.
19  Thus phase 1 detoxification capacity of 
CYP1A1 is influenced at 3 different levels; baseline expression level, expression 
induction, and enzymatic activity.
Several polymorphic allelic variants have now been described within the CYP1A1 
gene (reviewed in 
20).  The most common variant allele designated *2A, introduces a 
Msp1 restriction site in the 3' end of the gene. The next most common and potentially 
functionally more significant variant is a single nucleotide polymorphism in exon 7 
(A￿G) producing an isoleucine￿valine substitution at amino acid 462 (allelic variant 
designated *2B).  These alleles are often, but not always in linkage disequilibrium.
20
Whilst the data linking the *2A allele to high inducibility of CYP1A1 in human systems 
remain inconclusive,
21,22 the *2B allele does appear to increase induced gene 
expression and enzymatic function in lymphocytes from healthy donors with a 
significant trend through heterozygotes to homozygotes for the variant (Val) allele.
22
In this latter study CYP1A1 expression was particularly high amongst smokers with at 
least one *2B allele but was not elevated for smokers with at least one *2A allele.  
Thus augmented phase 1 metabolism resulting from high inducibility / increased 
expression of CYP1A1 upon exposure to environmental inducers / substrates will 
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lead to accumulation of toxic metabolic intermediates should phase 2 metabolic 
pathways be saturated.
The high concentration of PAH in cigarette smoke has led to extensive studies of 
CYP1A1 allelic variant frequencies in smoking-associated cancers.  Although most 
studies are small, the *2B allele may be over-represented in smokers developing 
lung,
23 breast
24 and colorectal
25 cancers.  Several studies provide plausible 
epidemiological support for the association between AML and substrates / inducers of 
CYP1A1. A cohort of subjects exposed accidentally to the potent CYP1A1 inducer 
TCDD have shown a 3.8-fold increased risk of myeloid leukemia with a latency of 15 
years.
26  Exposure to cigarette smoke is a weak but reasonably consistent risk factor 
for AML in large case-control studies.
27,28 Smoking history data was unfortunately not 
available for the majority of subjects in our study.  
NRAS mutations in our patients with the CYP1A1*2B allele show no signature 
mutation and this is perhaps not surprising given the diversity of putative 
environmental carcinogens in the etiology of AML.  It is of note however, that in those 
patients reported here and in our extended cohort of AML samples (data not shown), 
the majority of NRAS mutations are transitions, as has previously been reported in 
AML and other hematological malignancies.
29  Thus although PAHs are the most 
attractive candidate carcinogenic substrate of CYP1A1 in the etiology of AML, other 
substrates are likely to be involved based upon the mutation spectrum in our study.  
This may indeed be the case in other tumours, including lung cancer.  Although a 
signature p53 mutation spectrum is evident in cohorts of smokers with lung cancer, 
30
a recent study found a higher prevalence of p53 mutation in lung cancers from heavy 
smokers (compared with non-smokers) with variant CYP1A1 alleles (*2A/*2B) but the 
usual signature mutation spectrum was not found in this sub-group.
31 This suggests 
that the mutation signature may be less evident in patients with variant CYP1A1 
alleles.  Also in this study, smokers with a variant CYP1A1 allele had an increased 
frequency of KRAS mutation but the authors do not comment upon the mutation 
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spectrum.  Cigarette smoke contains a multitude of carcinogenic compounds in 
addition to both TCDD and PAHs.  Exposure to combinations of CYP1A1 inducers 
and substrates may therefore exacerbate the potential for genomic damage on the 
background of inheritance of the high-inducibility *2B allele.  A final alternative 
hypothesis is that reactive oxygen species known to be generated as a by-product of 
CYP1A1-mediated carcinogen metabolism
32,33 may oxidise DNA.  Oxidative DNA 
damage may generate a more diverse mutation spectrum including transitions (e.g. 
5OH-Cytosine G￿A) and transversions (8OH-Guanine G￿T).
It remains unclear why the association between the CYP1A1 *2B variant allele and 
NRAS mutation should be confined to the poor-risk karyotype groups.  In the context 
of therapy-related AML however, point mutations in critical regulatory genes are more 
common within the "deletional" karyotypes, namely p53 mutation associated with 
chromosome 5 deletion,
34 and RAS mutation associated with chromosome 7 
deletion.
1  These data suggest that genomic instability leads to AML through different 
pathways
1 and in the context of de novo AML, CYP1A1 variant allele status may 
represent one determinant of this instability. It is not surprising that FLT3 ITD is not 
associated with the CYP1A1 *2B allele within these cytogenetic subgroups as the ITD 
most likely arises from a different mechanism to point mutation, perhaps aberrant 
recombination or defective double strand DNA repair.
In conclusion, our data suggest that the variant CYP1A1*2B allele may predispose to 
the development of a sub-group of AML patients characterised by poor-risk 
karyotypes and NRAS mutation.  Epidemiological data also suggest that substrates / 
inducers of CYP1A1 represent candidates for environmental carcinogens with 
potential to cause AML but alternative mechanisms such as CYP1A1-induced 
oxidative stress are also proposed.
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